The "chain" is on the way, and the "Yantai Power" on the rise of the biomedical track

In the late summer and early autumn, refreshing and pleasant.

The Yantai Blue Medicine Valley · Life Island project on the banks of the fish and bird river in Muping District is still hot. The tower hangs the long arms, and the excavator opens the grabbing to install it as a slag car. "vitality".

YMG all media reporter Quanbaihui

Tan Jianzhao, deputy general manager of Yantai Biomedical Health Industry Development Group Co., Ltd., introduced that currently projects are mainly under construction projects with Yantai International Pharmaceutical Innovation Application Base and Industrialization of Regenea Medicine. The annual output value is 26 billion yuan. "

Yantai Blue Medicine Valley · Life Island project is a vivid portrayal of the high -quality development of Yantai biomedical industry. Since the implementation of the chain length system in July last year, Yantai biomedical industry focuses on the overall deployment of spatial layout of the "1+3+X" industrial park in the biomedical industry, based on the current status of the industry, facing future plans, in new drug research and development, high -end talent introduction, key projects, key projects Reserve and other aspects have achieved steady breakthroughs.

Looking at the territory of the high -end manufacturing industry today, the biomedical industry is showing a new scene that is full of expectations: several breakthroughs in cutting -edge areas, and the industrial innovation ecology has gradually changed. With the continued implementation of the chain length system, the development of the development of Yantai biomedical industry will also be further opened. On the golden track of the biomedical industry, the "Yantai Power" surged in a strong potential energy in the new round of revitalization and development of the country.

The biomedical industry chain "first proof"

Since the beginning of this year, Yantai biomedical industry has been surprised:

Yantai Blue Medicine Valley Life Island project starts;

The new crown vaccine of the latest technical route of the Green Leaf Life Science Group has entered the clinical trial stage abroad.

Rongchang Bio is officially listed on the Shanghai Stock Exchange Science and Technology Board and is the largest listed pharmaceutical company in Shandong Province.

The development of the biomedical industry is the best example of the "chain -long system" of Yantai to implement the "chain length system", and fully promote the integration of innovation chain and industrial chain.

As a key industry cultivated by Yantai, the biomedical industry has grown up a number of backbone enterprises in recent years, and a number of innovative products have emerged. However, the urgent need of innovation ability is still the main "bottleneck" that affects the high -quality development of the pharmaceutical industry.

New situation, new thinking. Cracking the bottleneck, Yantai's trial situation proposed that the biomedical industry implemented chain -long system, "9+N" industry in the city, "first proofed", set up a chain -long work class, focusing on innovative drugs, high -end raw materials, rehabilitation auxiliary tools and high -end high -end医疗器械、中医药、特医食品与保健食品、医疗健康大数据、医美产品、细胞与基因治疗八大细分领域，实行“一链长、一布局、一链办、一基金、一联盟、 One platform "working mechanism to promote industrial chain, extended chain, supplementary chain, and strong chain.

YMG All Media Reporter Liu Jie

The key to implementing the "chain length system" work mechanism is to establish a high -efficiency and overall command system, coordinate major matters on the chain such as industrial planning, policy implementation, park construction, platform construction, and element agglomeration to accelerate the professional agglomeration of the elements of the biomedical industry. At present, Yantai has established a rapid implementation of the implementation system and implemented the physical operation of chain. Implement the "one -library and four list" projects in the whole life cycle closed -loop management, establish the urban area vertical work acceptance mechanism, the department's horizontal joint service mechanism, and implement the "weekly adjustment, monthly promotion, seasonal observation, annual evaluation" work promotion mechanism, accurately dock Response project demands. At present, the full -chain is included in more than 300 enterprises in China Merchants Tan, and 68 projects are included in the closed -loop management list projects.

The development of chain is based on the collaboration system. To this end, Yantai determined the first batch of 10 chain main enterprises (Green Leaf Pharmaceutical, Rongchang Biology, Stone Medicine Baikk, Dongcheng Pharmaceutical, Runzhong Pharmaceuticals, Zhenghai Biological, Hongyuan Oxygen Industry In the new era), it has been held through many chain -owned enterprise symposiums to seek industrial chain, supply chain, innovation chain, talent chain, and policy chain coordination. These 10 chain main enterprises are intertwined, taking into account the current advantages and long -term development directions, and encourage enterprises, enterprises, capital, enterprises and technology, enterprises and markets to cooperate through platforms, alliances, etc. The integrated enterprise cluster of the central and lower reaches of the core cohesion to create a high -end industrial ecology aiming at the value chain. Since the beginning of this year, Yantai and Dongcheng Pharmaceuticals have jointly created a world -class medical isotopic drug industry chain on the Life Island of Blue Pharmaceutical, and jointly created an innovative vaccine industrialization base with Green Leaf Pharmaceuticals. Adopting alliances and strengthening the supporting supporting facilities of the supply chain industry chain. In 2022, the main enterprise of the chain was built with 6 new renewal projects and a total investment of 15.5 billion yuan.

Chain strategy navigation, this is another "bonus item" of the high -quality development of Yantai biomedical industry chain. At the international conference of 2021 Pharmaceutical Innovation and Development, Yantai officially released the "Several Opinions on Promoting the High -quality Development of the Biomedical Industry in the City". From the four aspects of task goals, organizational guarantees, characteristic parks, and support policies, "one opinion, two opinions, two Plan and one policy "have comprehensively clarified the key directions, development strategies, implementation paths, and policy guarantees of making breakthroughs in biomedicine in the next three years. Take this as an opportunity, Yantai biomedical industry will focus on supplementing shortcomings, raising levels, and building ecology. Focus on innovative drugs, high -end raw materials, rehabilitation auxiliary devices and high -end medical devices, Chinese medicine, special medical food and health food, medical and health big data, medical beauty products, cells and gene therapy eight major areas, implement innovation platforms, financial assistance The nine major projects such as attracting capacity and expansion to accelerate the establishment of a 100 billion industry in the 100 billion industries with the basic ecosystem, the overall strength of the industry and the great innovation capabilities. "Chain" -style innovation catalysis new kinetic energy

The "flash point" shown in the Yantai biomedical industry has largely reflects the transformation of industrial innovation ecosystem brought by chain -long system.

For a long time, the Yantai biomedical industry has been weaker in innovation and lacks heavy innovation results. However, with the turning point of the industrial development, the strong demand for changing its own endurance.

YMG All Media Reporter Liu Jie

Large enterprises, few scientific research institutions, lack of talents, and incomplete innovation supporting systems are important factor restricting the innovation and development of the biomedical industry. In response to these "weaknesses", under the guidance of the chain length system, Yantai started to strengthen and break the bottleneck of development.

Talent is the first resource for innovation. Yantai established the first biomedical industry talent alliance in the province. The Harbin University of Engineering Institute and Dongcheng Pharmaceuticals carried out school -enterprise cooperation to promote the joint construction platform of Binzhou Medical College, Shandong Hida Data Research Institute, and Yantai Biomedical Health Industry Development Group. At the same time, the establishment of the Institute of Innovation and Development of the Biomedical Industry is a think tank -type public welfare non -profit research institution jointly launched by the Yantai Municipal Government and Binzhou Medical College. Biomedical Industrial Think Tank ".

Fang Jianmin, a professor of biological professor Rongchang, said: "We can feel the support of the Yantai Municipal Government's support for all parties in the biomedical industry and the sincerity of the enterprises in the station. Convenient services, at the same time, excellent enterprises and projects can also get additional fund rewards, which greatly inspire our innovative genes and entrepreneurial confidence. "

The key to innovation is an efficient innovation platform. At present, Yantai has established a cloud platform for innovation and development of the biomedical industry to promote offline resources such as scientific research institutions, clinical research and development, key supply, financial capital, and expert talents. There are 140 key investment enterprises, with a total of more than 80,000 pharmaceutical research and development data and more than 4,000 project results. It is promoting the construction of the biomedical industry brain, focusing on industrial management and precision investment promotion to provide data platform support. Not only that, Yantai also further promoted the construction of the China Science and Technology High School (Yantai) Drug Advanced Research Institute, and focused on creating a major science and innovation platform for national new drug research and development and results transformation. "Shandong Provincial Postdoctoral Innovation Practice Base" determined. In the next step, the Institute of Drug Innovation of the Bohai Sea (Yantai) Bohai Sea (Yantai) will work hard to achieve a number of breakthrough results in the theory and key technology development of new drug creation.

The advantages of the chain -long system have begun to show. At present, the Yantai biomedical and health industry has been comprehensive, and the industrial park system has gradually improved, attracting a large number of well -known pharmaceutical companies, innovative talents and high -quality projects. Yantai has become an important creature in northern China. " Yaogu "is also the international preferred place for the innovation and development of the biomedical industry. At present, Yantai has formed a cluster of pharmaceutical research and development and production enterprises with green leaf pharmaceuticals, stone medicines, and Rongchang creatures.

Multiple empowerment to open "Yantai Medicine" to develop a new space

The chain length system makes the biomedical "Yantai make" more enough. However, for Yantai, which is ambitious to build a demonstration city of international life science innovation, the potential for biomedical development is still huge, excellent development environment, and strong innovation research and development. Become a new growth point and explosion point for the high -quality development of cities.

Yantai pharmaceutical industry is "family". At present, there are 127 companies in the field of Yantai biomedicine, with 55 companies with sales revenue exceeding 100 million yuan, 13 companies with more than one billion yuan. Five companies are listed in China and foreign countries. Six companies have entered the domestic pharmaceutical industry and business fields. Among them, there are head enterprises such as Rongchang, Green Leaf, and Shi Medicine, as well as a number of domestic single championships and unicorns such as Zhenghai Biological and Hongyuan Oxygen Industry, as well as young emerging companies such as Ding Ding Technology and Fengjin. Essence

YMG all media reporter letter

Regarding the current development situation, Tan Keliang, director of the Municipal Market Supervision Bureau, said, "Now our biomedical industry is in a rising period. As the chain length system continues to advance, it will usher in the" blowout period "in the future." As for how to achieve it, how to achieve it Sustainable and high -quality development, Tan Keliang believes that the key lies in the continuous advancement of key projects. The key to transforming the advantage is the key to achieving the first breakthrough lies in key projects. In 2021, 45 pharmaceutical projects have been registered. This year, Yantai continued to make efforts. It has been screened and brought together nearly 40 biomedical reserves, with a total investment of more than 30 billion yuan.

Relying on the technical advantages of the Green Leaf Pharmaceutical Reorganization Protein VLP Granules Vaccine Platform, the Shandong Vaccine Innovation and Industrialization Base Project is committed to creating an international vaccine base. At present, the production of clinical samples in the new crown vaccine is progressing smoothly, and the approval is advancing in an orderly manner.

China Science

A new type of R & D institution co -built by the Shanghai Institute of Pharmaceuticals and Yantai Municipal Government of China will build a national integrated platform for research and development of national high -end biomedicine through three phases to build a number of scientific research results in Yantai and Shandong Province.

Three billion -level corporate park expansion

Rongchang Biopharmaceutical Industrialization Project has a total investment of 5 billion yuan and a construction area of ​​261,000 square meters. It is mainly engaged in the industrialization of new drugs such as "Thai Sipp". Green Leaf Pharmaceutical Industrial Park Innovation Pharmaceutical Industrialization Project is used for China Test and Industrialization, and supports professional infrastructure and public service facilities. The total investment of the Shi Pharmaceutical Innovation Pharmaceutical Industrial Park project is 1 billion yuan, which mainly builds a GMP biopharmaceutical workshop and supporting facilities. It will settle in a number of new drugs in multiple countries with more than 2 billion yuan.

Accelerating the conversion of new and old kinetic energy, investment promotion is the key starting point. Since the beginning of this year, Yantai has promoted the establishment of a specialized market -oriented investment institution in the key areas of "1+3. Twenty head funds or enterprises have launched the door -to -door investment, precision investment promotion, and fund investment activities, and strive to introduce more than two new key enterprises, institutions, teams, and investment institutions in each key area. By actively strive for Pharmaceutical companies and institutions such as Stone Medicine Group, Xianyou Pharmaceuticals, Yuanda Group, Central Energy Conservation, and Sinopharm Shanghai Medical College, improve the strategic positioning of Yantai related enterprises and expand investment, add more than 3 new varieties, promote and vast major The group's "radioactive nuclear puppet drug R & D and production center" cooperation project landed. Focusing on industrial development and gathering, attract special new, gazelle, unicorn, and invisible champion companies with original innovation capabilities and mastering key core technologies.

The excellent market environment, the strong basic heritage, are lit the "innovation engine" of Yantai. In the next step, Yantai will rely on the "chain length system" to boldly innovate the practice, calling the "innovative medicine, Yantai manufacturing" brand, and build a "international life science demonstration city" to inject new kinetic energy into the innovation and development of the world's biomedical industry. Continue to write a new grand chapter for the high -quality development of Yantai in the new era.

YMG all -media reporter Gao Shao Shuai correspondent Sun Hong'an Photography Report

Editor in charge: Yang Yunge

- END -